Bristol-Myers Squibb, a biopharmaceutical company, has terminated the development of BMS-986094, an investigational NS5B nucleotide for the treatment of hepatitis C. Based on an ongoing assessment of patients in a Phase II study that the ...
Tags: BMS-986094, Bristol-Myers, hepatitis C, NS5B nucleotide